FLT3 and leukemia: Multiple mutations were only present in a small subclone of the entire leukemia population (NRAS mutation in AML2, 36 bp ins FLT3-ITD in AML12), since in both cases those subclones are derived from bigger subclones, the use of the other markers to keep track of the disease is more efficient for adequate MRD detection.